Browsing Tag
Hepatitis B
6 posts
GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval
GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more.
Sanofi bets $2.2bn on Dynavax to expand adult vaccine pipeline with hepatitis B and shingles focus
Find out how Sanofi’s $2.2B Dynavax buyout could reshape its adult vaccine strategy with HEPLISAV-B and a new shingles candidate in development.
Will Pictor’s targeted proteomics platform gain traction after CDC’s hepatitis B shift?
Pictor’s ViraScreen-Core test aligns with new CDC hepatitis B guidance. Find out how this multiplex assay could reshape antibody testing in clinical labs.
VRON-0200’s Spark and Fan model: Is Virion Therapeutics unlocking durable immunity against chronic hepatitis B?
Virion Therapeutics reports sustained immune responses up to one year after a single VRON-0200 dose for chronic HBV. Find out what makes this a potential game-changer.
Dynavax (NASDAQ: DVAX) targets 60% U.S. hepatitis B market share by 2030 amid COVID vaccine deal, $100m buyback
Dynavax targets 60% of U.S. hepatitis B vaccine market by 2030, expands COVID-19 pipeline, and authorizes $100M buyback. Read what this signals for investors.
GNI Group to halt enrolment in Phase 2 liver fibrosis trial following positive results
Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2…